Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_3
3
30%
Ph not_applicable
2
20%
Ph phase_1
1
10%
Ph phase_2
3
30%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
3(33.3%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 23 (33.3%)
Phase 33 (33.3%)
N/A2 (22.2%)

Trials by Status

completed990%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
terminatednot_applicable

Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi

NCT02499172
completedphase_3

Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™

NCT04760236
completed

Cholera Vaccine Investment Strategy in Bangladesh

NCT02727855
completedphase_2

PXVX0200 (CVD103-HgR) vs Shanchol in Mali

NCT02145377
completedphase_1

Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine

NCT02823899
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02499172Not Applicable

Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi

Terminated
NCT04760236Phase 3

Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™

Completed
NCT02727855

Cholera Vaccine Investment Strategy in Bangladesh

Completed
NCT02145377Phase 2

PXVX0200 (CVD103-HgR) vs Shanchol in Mali

Completed
NCT02823899Phase 1

Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine

Completed
NCT02027207Phase 3

Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh

Completed
NCT02742558Phase 2

Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine

Completed
NCT01339845Not Applicable

Introduction of Cholera Vaccine in Bangladesh

Completed
NCT01762930Phase 2

Field Application of Shanchol in Adults in Bangladesh

Completed
NCT02164110Phase 3

To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10